NMN vs. NR: The NAD+ Precursor Battle — What the Latest Human Trials Actually Show
NAD+ — nicotinamide adenine dinucleotide — is one of the most important molecules in aging biology. Its decline with age is among the most consistent findings in the field. But the two supplements most commonly used to raise NAD+ levels, NMN and NR, are marketed with claims that outrun the evidence. Here is a rigorous, up-to-date look at what we actually know.
✓ Cited Sources
- NAD+ levels fall with age in several human and animal tissues, which can reduce the activity of NAD+-dependent enzymes (sirtuins, PARPs) involved in DNA repair, gene regulation and mitochondrial function.
- Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) effectively raise blood NAD+ levels in humans. The clinical significance of this elevation remains an active area of research.
- Human trials so far are mostly small and short (weeks to months) and measure surrogate endpoints such as blood NAD+ and insulin sensitivity rather than health outcomes. No long-term human outcome data exist for either compound.
- The weight of current evidence slightly favors NMN over NR in terms of tissue-specific delivery — particularly to muscle, where NR may not efficiently convert — but this remains contested in the literature.
- Lifestyle comes first. Exercise, particularly endurance exercise, raises NAD+ in muscle, and limiting what drains NAD+, such as heavy drinking, matters more than any supplement.
In 2013, David Sinclair's lab at Harvard reported that a week of NMN restored mitochondrial function and other markers of aging in the muscle of old mice.[1] The findings drew enormous attention, and NMN and NR became some of the best-selling longevity supplements.
But the mice were not people, and the years since have produced a more complicated and more honest picture of what NAD+ supplementation does in humans. This article brings that evidence together, including the most recent clinical trials.
Why NAD+ Matters: The Mechanistic Case
NAD+ is a coenzyme found in every cell of the body, essential to hundreds of metabolic reactions. It serves two primary roles: as an electron carrier in energy metabolism (the NAD+/NADH redox couple at the heart of the Krebs cycle and oxidative phosphorylation), and as a substrate for a class of NAD+-consuming signaling enzymes — primarily sirtuins and PARPs — that regulate some of the most important longevity-relevant processes in biology.[2]
The seven sirtuins (SIRT1–7) use NAD+ to remove acetyl groups from proteins, thereby regulating gene expression, mitochondrial function, inflammation, and DNA repair. SIRT1 and SIRT3 are particularly important for longevity — their activity declines with age, and this decline is at least partially attributable to falling NAD+ levels. PARP enzymes, which repair DNA strand breaks, also consume large quantities of NAD+. As DNA damage accumulates with age, PARP activity increases — draining NAD+ and further reducing sirtuin activity in a vicious cycle.[3]
This mechanistic chain — NAD+ decline → reduced sirtuin and PARP activity → accelerated epigenetic aging, impaired DNA repair, mitochondrial dysfunction — is compelling and internally consistent. It is why NAD+ precursors have attracted so much scientific attention. The question is whether supplementing NAD+ precursors in humans actually activates this pathway in clinically meaningful ways.
NMN and NR: The Key Differences
Both NMN and NR are NAD+ precursors — molecules that the body converts into NAD+. NR (nicotinamide riboside) is converted to NMN by the enzyme NRK1/2, which then enters the NAD+ biosynthesis pathway. NMN (nicotinamide mononucleotide) enters the pathway one step further downstream — closer to NAD+ — and may be transported into cells via the Slc12a8 transporter, which is expressed in the small intestine and some other tissues.[4]
The theoretical advantage of NMN is that it bypasses the NRK1/2 conversion step, potentially allowing more efficient NAD+ production in tissues where NRK1/2 activity is limiting. The theoretical advantage of NR is that it has been studied longer in humans, has more published clinical trial data, and is generally less expensive.
| Characteristic | NMN | NR |
|---|---|---|
| Molecular weight | 334 g/mol | 255 g/mol |
| Steps to NAD+ | 1 step | 2 steps |
| Raises blood NAD+ | Yes, in trials | Yes, in trials |
| Muscle outcomes | Improved muscle insulin sensitivity in one small trial of women with prediabetes[8] | No insulin-sensitivity benefit in a 12-week trial in obese men[7] |
| Long-term human outcome data | None | None |
What Human Trials Actually Show
Before reviewing the trial data, a critical caveat: the human evidence base for both NMN and NR is still in its early stages. Most published trials are small, short, and focused on intermediate biomarkers rather than clinical outcomes. No randomized controlled trial has demonstrated that either compound extends human lifespan or meaningfully reduces age-related disease incidence. Extrapolating from mouse data or surrogate endpoints to longevity claims requires enormous epistemic caution.[5]
NR: The More-Studied Compound
The strongest NR human data comes from Charles Brenner's group and from trials sponsored by ChromaDex, which sells NR. NR consistently raises blood NAD+ levels, with higher doses giving larger increases. In a 2018 trial in healthy middle-aged and older adults, NR raised NAD+ in blood cells and was well tolerated.[6] Functional outcomes such as insulin sensitivity, muscle function, inflammation and blood pressure have improved inconsistently across trials; a 12-week trial in obese men found no improvement in insulin sensitivity despite raising NAD+-related metabolites.[7]
NMN: The Newer Contender
A 2021 trial by Yoshino et al. at Washington University is the most rigorous NMN study so far. In a double-blind trial of 25 postmenopausal women with prediabetes and overweight or obesity, NMN (250 mg a day for 10 weeks) increased muscle insulin sensitivity and insulin signaling, changes not seen with placebo.[8] The trial was small but well designed.
In a 2022 Japanese trial in healthy older men, NMN (250 mg a day for 12 weeks) raised blood NAD+ and produced nominally significant improvements in gait speed and left-hand grip strength, which the authors say need confirming in larger studies.[9]
Most trials measure NAD+ in blood. Whether oral NMN or NR raises NAD+ in the brain, liver or other organs in humans is not known, so claims about brain benefits in particular are speculative.
A 2026 pilot trial shows the gap between raising NAD+ and improving health. In 42 older adults with amnestic mild cognitive impairment, 12 weeks of nicotinamide riboside doubled blood NAD+ but did not improve cognitive function, the primary outcome, or overall brain blood flow.12
The Lifestyle Foundation: Don't Supplement Over a Broken Foundation
The most consistent and powerful ways to raise NAD+ levels remain lifestyle interventions, not supplements. This does not diminish the potential role of NMN or NR — it contextualizes it.
Exercise raises NAD+ in muscle. In animal studies, AMPK activation during exercise increases NAD+ levels and SIRT1 activity.[10]
Caloric restriction and fasting raise NAD+ levels and sirtuin activity in animal studies.[3]
Reducing alcohol helps because alcohol metabolism converts NAD+ to NADH, lowering the NAD+/NADH ratio in the liver; heavy drinking adds to the strain.
Who Should Consider NMN or NR?
Given the current evidence, the case for NAD+ supplementation is most plausible in: people over 50 whose lifestyle is already optimized (exercise, diet, sleep, stress management); people with confirmed metabolic dysfunction (insulin resistance, type 2 diabetes) where muscle NAD+ depletion is mechanistically implicated; and people with conditions thought to increase NAD+ consumption (inflammatory diseases, active DNA repair demands). For healthy people under 40 with good lifestyle habits, the marginal benefit is likely small and the cost-benefit analysis less favorable.[11]
Put this research into practice: Supplement Evidence Database · Supplement Interaction Checker
References
- 1Gomes AP, et al. "Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624-38. PubMed · DOI
- 2Cantó C, et al. "NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus." Cell Metab. 2015;22(1):31-53. PubMed · DOI
- 3Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends Cell Biol. 2014;24(8):464-71. PubMed · DOI
- 4Grozio A, et al. "Slc12a8 is a nicotinamide mononucleotide transporter." Nat Metab. 2019;1(1):47-57. PubMed · DOI
- 5Fang EF, et al. "NAD(+) in Aging: Molecular Mechanisms and Translational Implications." Trends Mol Med. 2017;23(10):899-916. PubMed · DOI
- 6Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults." Nat Commun. 2018;9(1):1286. PubMed · DOI
- 7Dollerup OL, et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." Am J Clin Nutr. 2018;108(2):343-353. PubMed · DOI
- 8Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229. PubMed · DOI
- 9Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." NPJ Aging. 2022;8(1):5. PubMed · DOI
- 10Cantó C, et al. "AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity." Nature. 2009;458(7241):1056-60. PubMed · DOI
- 11Nadeeshani H, et al. "Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns." J Adv Res. 2022;37:267-278. PubMed · DOI
- 12Martens CR, et al. "A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment." Alzheimers Dement. 2026;22(7):e71605. PubMed · DOI